Anil Bajnath, MD

03/02/2026

Chronic disease rarely begins the day we diagnose it.

It begins when biological systems start to drift from stability.

New research highlights the importance of longitudinal, high-resolution phenotyping. Instead of relying on single lab values at a single time point, this approach tracks patterns over time. Subtle shifts in metabolic, inflammatory, and molecular networks can signal early destabilization long before traditional diagnostic thresholds are crossed.

This changes how we think about “normal.”

Two people may have identical lab results today. But their trajectories over time may be very different. One may be stable. The other may already be trending toward dysfunction.

Precision medicine is increasingly about detecting these trajectory shifts rather than waiting for numbers to become abnormal.

Prevention, in this model, is not reactive. It is anticipatory.

The future of clinical care may depend less on isolated test results and more on understanding patterns, variability, and system-level stability.

Normal does not always mean healthy. Stability may matter more.

02/27/2026

Senolytic therapies are often described as a way to “reset” aging biology by clearing senescent cells.

A new study suggests the story is more nuanced.

Researchers examined the DNA methylation patterns associated with cellular senescence and found that even after senolytic treatment reduced senescent cell burden, the characteristic epigenetic signatures of senescence were not fully reversed.

In other words, removing the cells does not necessarily erase the molecular imprint they leave behind.

This distinction matters.

Aging is layered. Some features may be functionally improved by eliminating damaged cells, such as reducing inflammation or improving tissue performance. But deeper regulatory marks — like DNA methylation patterns — may persist.

For those interested in longevity and precision medicine, this highlights an important principle: improving phenotype is not the same as fully resetting biological age.

Understanding which aspects of aging are reversible and which are durable will shape the next generation of interventions.

The difference between clearing and reprogramming is more than semantic — it is mechanistic.

02/26/2026

Blood-based biomarkers for Alzheimer’s disease are improving rapidly.

But one critical issue remains: signal contamination from the periphery.

Amyloid-beta in plasma is not derived exclusively from the brain. It is influenced by systemic metabolism, peripheral production, kidney and liver clearance, and comorbid conditions. That reduces the signal-to-noise ratio when we try to detect cerebral pathology from a routine blood draw.

This study explored a straightforward but conceptually important idea: draw blood closer to the source.

When sampled from the internal jugular vein — anatomically proximal to the brain — the Aβ42/40 ratio showed stronger correlation with amyloid PET burden, higher diagnostic accuracy, and fewer indeterminate classifications compared to standard peripheral sampling.

No new molecule.
No new assay.
Just improved biological fidelity.

This is an important reminder that precision medicine is not only about discovering novel biomarkers. It is also about optimizing how and where we measure them.

Signal quality determines diagnostic precision.

And sometimes, proximity matters.

02/25/2026

Cancer cachexia is often described as weight loss associated with advanced cancer.

That description barely captures the biology.

A new study developed human neuromuscular organoids from induced pluripotent stem cells to model how tumors affect muscle tissue. When these organoids were exposed to media from pro-cachectic cancer cells, they developed key features of muscle wasting: fiber atrophy, reduced contractile strength, metabolic disruption, mitochondrial dysfunction, and increased autophagy.

Importantly, there were no tumor cells directly invading the tissue. The effect was driven by factors secreted by the cancer.

This reinforces an important principle: cancer is not confined to the primary tumor. It exerts systemic metabolic and inflammatory pressure that can reprogram distant tissues.

Understanding these cross-organ effects is critical if we want to preserve muscle function, resilience, and quality of life during cancer treatment.

Precision oncology is not only about targeting mutations. It is also about protecting the host.

The more accurately we can model these systemic interactions in human-relevant systems, the closer we move toward interventions that address not just tumor control, but whole-body health.

02/23/2026

For more than a century, diagnosing cellular abnormalities has relied on trained experts looking through microscopes.

That model works — but it is labor intensive, subjective, and increasingly strained by workforce shortages.

A new AI-driven cytology platform reimagines this process. Instead of reviewing static images, it scans entire slides in three dimensions, reconstructs focal layers in real time, identifies individual nuclei, and classifies cells before generating a quantitative “census” of cellular states across the whole slide.

This is more than automation.

It is a redesign of how we measure disease.

Rather than forcing cells into simple normal versus abnormal categories, the system maps them along gradients of probability. That shift reflects a broader truth in medicine: disease is rarely binary. It exists along a spectrum.

From a precision medicine perspective, this matters deeply. Before we can personalize treatment or predict risk, we must first measure phenotype consistently and at scale. High-fidelity cellular assessment is the foundation of accurate stratification.

The future of cancer screening and diagnostic pathology may depend not only on better therapies, but on better measurement.

The microscope is evolving — and with it, the way we define disease.

https://www.nature.com/articles/d41586-026-00288-3

02/20/2026

Most of us were taught that mitochondria are simply the “power plants” of the cell.

That story is incomplete.

Emerging research shows that when mitochondria become stressed or damaged, they can release fragments of their own DNA into the cell and bloodstream. The immune system interprets this as a danger signal, activating inflammatory pathways that were originally designed to fight infection.

In other words, metabolic stress can turn into immune activation.

This may help explain why two people with similar cholesterol, glucose levels, or diagnoses can have very different health trajectories. Beneath standard lab results, there may be differences in mitochondrial stability that influence inflammation, resilience, and disease progression.

From a precision medicine perspective, this is important. Health is not just about isolated numbers. It is about how biological systems communicate with one another. Mitochondria sit at the intersection of metabolism and immunity, and when that communication becomes distorted, chronic disease risk may rise.

As we think about aging, cardiometabolic disease, neurodegeneration, and even cancer, preserving mitochondrial integrity may be as important as correcting downstream biomarkers.

The future of medicine will increasingly focus on maintaining signaling balance between systems rather than simply reacting to symptoms.

02/19/2026

Precision medicine represents a structural shift in how we approach metabolic health and longevity.

It’s not just about running more labs. It’s about organizing complex multi-omic and exposomic data into clear biochemical pathways that guide clinical decisions.

In the next Precision Protocol Series, Anil Bajnath, MD and .vermeire will break down:
• The distinction between functional and precision medicine
• How multi-omic profiling becomes actionable
• Why exposomics is one of the most important emerging frontiers
• How to apply these frameworks in real-world practice

📅 February 24 at 12 PM PT
Live session — bring your questions.
Comment “RSVP” below and we’ll share the registration link.

10/14/2025

https://www.linkedin.com/posts/anil-bajnath-md-mba-ifmcp-abaarm-61204432_longevitymedicine-autophagy-agingresearch-activity-7383844891006611456-A4YL?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAbEwm4BSemaPj3SdyWOHqFgtpRy7BWyGoc

Rethinking Autophagic Cell Death: A Call for Causality in Longevity Science In the quest to decode the mechanisms of aging, autophagy stands as one of the most profound cellular survival processes — the body’s innate recycling system that clears damaged proteins, misfolded molecules, and dysfunc...

10/07/2025

https://www.linkedin.com/posts/anil-bajnath-md-mba-ifmcp-abaarm-61204432_longevitymedicine-cancergenomics-agingresearch-activity-7381315864744341504-V7G8?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAbEwm4BSemaPj3SdyWOHqFgtpRy7BWyGoc

Can aging itself be the architect of cancer evolution? A new study from Harvard Medical School and Massachusetts General Hospital, titled “Age distinguishes selection from causation in cancer genomes” (Cheek et al., 2025), offers a paradigm-shifting view of cancer biology through the lens of agi...

10/06/2025

https://www.linkedin.com/posts/anil-bajnath-md-mba-ifmcp-abaarm-61204432_longevitymedicine-inflammaging-aiinhealthcare-activity-7380948936079085569-fsVa?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAbEwm4BSemaPj3SdyWOHqFgtpRy7BWyGoc

Can the human face serve as a window into systemic inflammation and biological aging? A groundbreaking study from the Buck Institute for Research on Aging suggests that it can. Researchers led by David Furman, PhD, introduced Healthy Selfie—a deep learning algorithm capable of estimating Inflammat...

09/18/2025

https://www.linkedin.com/posts/anil-bajnath-md-mba-ifmcp-abaarm-61204432_mitochondrial-antioxidant-found-to-drive-activity-7374426859117264896-zAFU?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAbEwm4BSemaPj3SdyWOHqFgtpRy7BWyGoc

Antioxidants are often viewed as universally protective — but new research reveals they may also play a darker role in cancer biology. A recent study in Cancer Discovery shows that mitochondrial glutathione, imported via the transporter SLC25A39, actively drives breast cancer metastasis. Rather th...

08/29/2025

https://www.linkedin.com/posts/anil-bajnath-md-mba-ifmcp-abaarm-61204432_ultra-processed-foods-upfs-are-no-longer-activity-7367172947800764417-XpVu?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAbEwm4BSemaPj3SdyWOHqFgtpRy7BWyGoc

Ultra-processed foods (UPFs) are no longer just a nutrition debate — they are emerging as endocrine disruptors in plain sight. A new randomized controlled trial published in Cell Metabolism dissects the direct effects of UPF consumption in healthy young men. By matching caloric intake between UPF ...